| BIOGEN INC. DL -,0005 | 202.55 / -1.36% |
| Date/Time | 05/24 / 19:35 |
| Chg. / Chg.(%) | -2.80 / -1.36% |
| Bid | 201.60 / 174 |
| Ask | 202.55 / 173 |
| Open | 204.90 |
| Previous Close | 205.35 |
| High | 206.50 |
| Low | 202.55 |
| Volume [EUR] | 0.00 |
| Volume [Units] | 0 |
| Price fixings | 15 |
| ISIN | US09062X1037 |
| Security | IDP |
| Exchange | Berlin |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 201.594 |  |
|
| NASDAQ | 227.0600 | |
1,792,500 |
| Cboe US | 226.99 | |
126,736 |
| IEX | 226.99 | |
64,120 |
| TradeGate | 202.000 | |
1,981 |
| London Inter.. | 227.21 |  |
1,190 |
| Frankfurt | 204.650 | |
400 |
| Xetra | 204.00 | |
174 |
| Stuttgart | 202.400 | |
38 |
| Vienna Globa.. | 203.63 | |
0 |
| München | 203.90 | |
0 |
| Hamburg | 203.90 | |
0 |
| Düsseldorf | 203.75 | |
0 |
| Berlin | 202.55 | |
0 |
| Hannover | 203.90 | |
0 |
| SIX Swiss Ex.. | 232.00 | |
|
| gettex | 202.500 | |
|
| Mexico | 4,453.00 | 544 |
News
- Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation
05/20/2019 / 13:30 - GlobeNewswire - Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy
05/15/2019 / 01:02 - GlobeNewswire - Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS
05/07/2019 / 13:30 - GlobeNewswire - Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)
05/06/2019 / 13:30 - GlobeNewswire - Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)
05/01/2019 / 22:30 - GlobeNewswire
Real-time